SAN FRANCISCO and SUZHOU, China, May 28, 2024 /PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that picankibart (R & D code: IBI112), a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, has met all.
Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA | Taiwan News taiwannews.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taiwannews.com.tw Daily Mail and Mail on Sunday newspapers.
Tumors are not just isolated clumps of abnormal cells, but are associated with more complex system known as the "tumor microenvironment" (TME). Over the past few years, research has revealed that the TME consists of a complex combination of blood vessels, connective tissue, and a matrix of extracellular proteins and molecules. Most importantly, the composition of the TME is different from that of nearby healthy tissues. In particular, the lipid and collagen contents of tumors differ from those of normal tissues, making them important potential biomarkers for diagnosing various types of cancers, such as breast, prostate, or skin cancer.
The patch emits painless sound waves that prise open tiny channels in the skin, allowing painkillers and other drugs stored inside the patch to rapidly pass through into the body.